At the news
? NEUTRALIMPACT 3/10 SC 13G filed Nov 9, 2026 at 13:23 ET
Coastlands Capital LP disclosed a new 5.14% passive stake in Sutro Biopharma, holding 852,669 shares as of November 5, 2026. This is a new 13G filing, not an amendment, indicating a fresh position crossing the 5% threshold. The stake is modest in size and the fund certifies passive intent, making this a routine disclosure with limited immediate price impact.
- Coastlands Capital LP filed a new Schedule 13G disclosing beneficial ownership of 852,669 shares of Sutro Biopharma common stock.
- The stake represents 5.14% of shares outstanding, based on 16,581,171 shares outstanding as of August 7, 2026.
- The filing certifies passive intent under Rule 13d-1(b) and (c), with no purpose of changing or influencing control.
- The shares are held directly by Coastlands Capital Partners LP; the reporting persons include Coastlands Capital LP, Coastlands Capital Partners LP, Coastlands Capital GP LLC, Coastlands Capital LLC, and Matthew D. Perry.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access